Affiliation:
1. Duke University (email: )
2. University of Texas (email: )
Abstract
We explore how the U.S. Patent and Trademark Office may improve the quality of issued patents on “secondary” drug features by giving examiners more time to review drug patent applications. Our findings suggest that current time allocations are causing examiners to issue low-quality secondary patents on the margin. To assess the merits of expanding ex ante scrutiny of drug patent applications at the agency, we set forth estimates of the various gains and losses associated with giving examiners more time, including reduced downstream litigation costs and added personnel expenses, along with both the static gains and dynamic innovation losses associated with earlier generic entry. (JEL K11, L65, O31, O34, O38)
Publisher
American Economic Association
Subject
General Economics, Econometrics and Finance
Reference81 articles.
1. An Empirical Analysis of Primary and Secondary Pharmaceutical Patents in Chile
2. Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry
3. Aitken, Murray L., Ernst R. Berndt, Barry Bosworth, Iain Cockburn, Richard Frank, Michael Kleinrock, and Bradley T. Shapiro. 2018. "The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity." In Measuring and Modeling Health Care Costs, edited by Ana Aizcorbe, Colin Baker, Ernst R. Berndt, and David M. Cutler, 243-271. Chicago: University of Chicago Press.
4. Secondary Patenting Of Branded Pharmaceuticals: A Case Study Of How Patents On Two HIV Drugs Could Be Extended For Decades
5. Promotions and the Peter Principle*